{"id":"NCT01525615","sponsor":"Boehringer Ingelheim","briefTitle":"A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2012-02-03","resultsPosted":"2015-09-15","lastUpdate":"2016-08-29"},"enrollment":404,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DEVICE","name":"Respimat inhaler","otherNames":[]},{"type":"DRUG","name":"tiotropium+olodaterol (low dose)","otherNames":[]},{"type":"DRUG","name":"tiotropium + olodaterol (high dose)","otherNames":[]},{"type":"DEVICE","name":"Respimat inhaler","otherNames":[]},{"type":"DEVICE","name":"Respimat inhaler","otherNames":[]},{"type":"DRUG","name":"placebo to tiotropium+olodaterol","otherNames":[]}],"arms":[{"label":"tiotropium+olodaterol low dose","type":"EXPERIMENTAL"},{"label":"tiotropium+olodaterol high dose","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD.","primaryOutcome":{"measure":"Adjusted Mean Endurance Time During Constant Work Rate Cycle Ergometry (CWRCE) After 12 Weeks","timeFrame":"12 weeks","effectByArm":[{"arm":"Placebo","deltaMin":463.63,"sd":18.813},{"arm":"Tio+Olo 2.5 / 5.0 µg","deltaMin":503.64,"sd":19.642},{"arm":"Tio+Olo 5.0 / 5.0 µg","deltaMin":527.51,"sd":20.154}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0209"},{"comp":"OG000 vs OG001","p":"0.1419"},{"comp":"OG001 vs OG002","p":"0.3970"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States","Argentina","Canada","Finland","France","Germany","Hungary","Italy","Spain","United Kingdom"]},"refs":{"pmids":["29439648"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":132},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Cough"]}}